Zhongsheng Pharmaceutical (002317.SZ): Onradivir tablets approved for marketing by the State Drug Administration

Zhitong Finance App News, Zhongsheng Pharmaceutical (002317.SZ) issued an announcement. On May 22, 2025, the China Drug Administration (hereinafter referred to as the “State Drug Administration”) website published a notice “The State Drug Administration approves the listing of Onradivir tablets”. The company's holding subsidiary Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd. (hereinafter referred to as “Zhongsheng Ruichuang”) was approved for marketing by the State Drug Administration. ZSP1273

Onradivir tablets are the world's first influenza RNA polymerase PB2 protein inhibitor with a clear mechanism of action and global independent intellectual property rights. It is suitable for the treatment of adult patients with simple influenza A.